公开(公告)号：WO2007064917A2

公开(公告)日：2007-06-07

申请号：PCT/US2006046043

申请日：2006-11-30

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG ,  HOLZMAN THOMAS F ,  HARLAN JOHN E ,  EDALJI ROHINTON P ,  OLEJNICZAK EDWARD T ,  PERADA-LOPEZ ANA ,  LABKVOSKY BORIS ,  YU LIPING

Inventor： HOLZMAN THOMAS F ,  HARLAN JOHN E ,  EDALJI ROHINTON P ,  OLEJNICZAK EDWARD T ,  PERADA-LOPEZ ANA ,  LABKVOSKY BORIS ,  YU LIPING

IPC: C07K14/43

CPC classification number: C07K14/4711 ,  A61K38/00 ,  C07K16/18

Abstract: The subject invention relates to the cloning, expression and isolation of recombinant forms of beta-amyloid protein containing a N-terminal methionine (or one or more amino acids) as well as to methods of using this recombinant protein in the production of therapeutic antibodies, in the identification of therapeutic small molecules, and in the performance of diagnostic assays.

Abstract translation: 本发明涉及含有N-末端甲硫氨酸（或一种或多种氨基酸）的重组形式的β-淀粉样蛋白的克隆，表达和分离以及在制备治疗性抗体中使用该重组蛋白的方法， 在鉴定治疗性小分子时，以及在诊断测定中的表现。

公开(公告)号：WO03090666A2

公开(公告)日：2003-11-06

申请号：PCT/EP0304900

申请日：2003-04-25

Applicant: KAROBIO AB ,  ABBOTT LAB ,  JAKOB CLARISSA G ,  MUCHMORE STEVEN ,  KAUPPI BJOERN ,  FARNEGAARDH MATHIAS ,  HARLAN JOHN E ,  YANG JIE ,  CARLQUIST MATS ,  ENGSTROEM OWE ,  AHOLA HARRI ,  OEHMAN LARS

Inventor： JAKOB CLARISSA G ,  MUCHMORE STEVEN ,  KAUPPI BJOERN ,  FARNEGAARDH MATHIAS ,  HARLAN JOHN E ,  YANG JIE ,  CARLQUIST MATS ,  ENGSTROEM OWE ,  AHOLA HARRI ,  OEHMAN LARS

IPC: A61K20060101 ,  C07K14/72 ,  G01N33/48 ,  G06F19/00 ,  A61K

CPC classification number: C07K14/72 ,  G01N33/48 ,  G06F19/00 ,  Y02A90/26

Abstract: The present invention is in the fields of biotechnology, protein purification and crystallization, x-ray diffraction analysis, three-dimensional computer molecular modeling and rational drug design. The invention is directed to the glucocorticoid receptor and ligands for this receptor, and in particular to crystalline glucocorticoid receptor (GR) and to methods of identifying ligands utilizing GR, as well as to compounds, compositions and methods for selecting, making, and using therapeutic or diagnostic agents having GR modulating or binding activity.

Abstract translation: 本发明涉及生物技术，蛋白质纯化和结晶，X射线衍射分析，三维计算机分子建模和合理药物设计领域。 本发明涉及用于该受体的糖皮质激素受体和配体，特别是结晶糖皮质激素受体（GR）和鉴定使用GR的配体的方法，以及用于选择，制备和使用治疗的化合物，组合物和方法 或具有GR调节或结合活性的诊断剂。

公开(公告)号：WO2009136382A2

公开(公告)日：2009-11-12

申请号：PCT/IB2009051915

申请日：2009-05-08

Applicant: ABBOTT GMBH & CO KG ,  ABBOTT LAB ,  GU JIJIE ,  HSIEH CHUNG-MING ,  WU ZHEN ,  DIGIAMMARINO ENRICO L ,  LUO FENG ,  FOX GERARD B ,  HARLAN JOHN E ,  SCHMIDT MARTIN ,  LOEBBERT RALF ,  MUELLER REINHOLD ,  EBERT ULRICH ,  NIMMRICH VOLKER

Inventor： GU JIJIE ,  HSIEH CHUNG-MING ,  WU ZHEN ,  DIGIAMMARINO ENRICO L ,  LUO FENG ,  FOX GERARD B ,  HARLAN JOHN E ,  SCHMIDT MARTIN ,  LOEBBERT RALF ,  MUELLER REINHOLD ,  EBERT ULRICH ,  NIMMRICH VOLKER

IPC: C12N15/12 ,  C12N5/00 ,  C12N7/00

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/464 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  C12P21/005

Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid ß and advanced glycation-end-products.

Abstract translation: 本申请涉及分离的蛋白质，特别是单克隆抗体，特别是结合RAGE蛋白质的CDR-移植的人源化抗体。 具体地说，这些抗体具有抑制RAGE与其各种配体结合的能力。 本申请中描述的抗体或其部分可用于治疗由RAGE的病理生理学配体表征或诱导的疾病或病症，例如错折叠蛋白，如淀粉样蛋白β和晚期糖基化终产物。

公开(公告)号：WO0234909A3

公开(公告)日：2003-11-13

申请号：PCT/US0148040

申请日：2001-10-26

Applicant: ABBOTT LAB

Inventor： STEWART KENT D ,  STEFFY KEVIN R ,  KEMPF DALE J ,  HARRIS KEVIN S ,  HUTH JEFFREY R ,  STOLL VINCENT S ,  HARLAN JOHN E ,  NG IOK C ,  BETZ STEPHEN F

IPC: G01N33/566 ,  C07K14/16 ,  C07K16/10 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12P21/02 ,  C40B30/04 ,  G01N33/15 ,  G01N33/50 ,  G01N33/569 ,  G01N33/58 ,  G01N33/68 ,  C12N15/11

CPC classification number: C40B30/04 ,  C07K14/005 ,  C07K2319/00 ,  C12N2740/16122 ,  G01N33/56988 ,  G01N33/6842 ,  G01N33/6845 ,  G01N2500/04

Abstract: The subject invention encompasses novel proteins related to the human immunodeficiency virus (HIV-1) gp41 protein and to methods of use thereof. For example, the proteins may be utilized in the screening of anti-HIV compounds.

Abstract translation: 本发明涵盖与人免疫缺陷病毒（HIV-1）gp41蛋白相关的新型蛋白质及其使用方法。 例如，蛋白质可用于筛选抗HIV化合物。

公开(公告)号：DOP2010000334A

公开(公告)日：2010-11-30

申请号：DO2010000334

申请日：2010-11-05

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG

Inventor： SCHMIDT MARTIN ,  GU JIJIE ,  HSIEH CHUNG-MING ,  WU ZHEN ,  DIGIAMMARINO ENRICO L ,  LUO FENG ,  FOX GERARD B ,  HARLAN JOHN E ,  LOEBBERT RALF ,  MUELLER REINHOLD ,  EBERT ULRICH ,  NIMMRICH VOLKER

Abstract: Proteínas aisladas, en particular anticuerpos monoclonales, en particular anticuerpos humanizados, con injertos de CDR, que se unen a una proteína RAGE. Específicamente, estos anticuerpos tienen la capacidad de inhibir la unión de RAGE a sus diversos ligandos. Los anticuerpos, o porciones de los mismos, que se describen en la presente solicitud son de utilidad para el tratamiento de una enfermedad o trastorno caracterizado por, o inducido por, ligandos fisiopatológicos de RAGE, por ejemplo proteínas mal plegadas como el ß amiloide y productos finales de glicosilación avanzada.

公开(公告)号：CA2723219A1

公开(公告)日：2009-11-12

申请号：CA2723219

申请日：2009-05-08

Applicant: ABBOTT GMBH & CO KG ,  ABBOTT LAB

Inventor： GU JIJIE ,  HSIEH CHUNG-MING ,  WU ZHEN ,  DIGIAMMARINO ENRICO L ,  LUO FENG ,  FOX GERARD B ,  HARLAN JOHN E ,  SCHMIDT MARTIN ,  LOEBBERT RALF ,  MUELLER REINHOLD ,  EBERT ULRICH ,  NIMMRICH VOLKER

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/46 ,  C12N15/13

Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid ß and advanced glycation-end-products.

公开(公告)号：CA2365300A1

公开(公告)日：2000-09-21

申请号：CA2365300

申请日：2000-03-01

Applicant: ABBOTT LAB

Inventor： BUKO ALEXANDER M ,  TANG QING ,  LADROR URI S ,  SOLOMON LARRY R ,  HOLZMAN THOMAS F ,  HARLAN JOHN E ,  EGAN DAVID A

IPC: G01N33/50 ,  C12Q1/02 ,  C12Q1/68 ,  C12Q1/70 ,  C40B30/00 ,  C40B40/02 ,  C40B50/06 ,  G01N33/15 ,  G01N33/53 ,  G01N33/567

Abstract: Centrifugation is used to induce and/or enhance binding between macromolecul ar targets and either small-molecule ligands or larger biomolecules as single entities or mixtures. With the enhanced binding, the method of the invention permits detection of ligands that bind to target substances and improve the design of ligands. The process relies on centrifugal force to establish a differential and selective concentration gradient between macromolecular therapeutic targets and the desired ligands. Once formed, the information about the self-sorting binding events is derived by analyzing the differenti al gradient of macromolecules and ligands in situ or by fractionating the gradient into individual samples for independent analysis. A variety of methods or combinations thereof, can be used to look for enhanced levels of bound ligands.

公开(公告)号：ZA201007885B

公开(公告)日：2011-07-27

申请号：ZA201007885

申请日：2010-11-03

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG

Inventor： FOX GERARD B ,  DIGIAMMARINO ENRICO L ,  LOEBBERT RALF ,  HARLAN JOHN E ,  LUO FENG ,  WU ZHEN ,  HSIEH CHUNG-MING ,  NIMMRICH VOLKER ,  GU JIJIE ,  SCHMIDT MARTIN ,  EBERT ULRICH ,  MUELLER REINHOLD

Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid ß and advanced glycation-end-products.

公开(公告)号：AR071698A1

公开(公告)日：2010-07-07

申请号：ARP090101682

申请日：2009-05-08

Applicant: ABBOTT GMBH & CO KG ,  ABBOTT LAB

Inventor： LOEBBERT RALF ,  WU ZHEN ,  GU JIJIE ,  HSIEH CHUNG-MING ,  FOX GERARD B ,  SCHMIDT MARTIN ,  HARLAN JOHN E ,  LUO FENG ,  MUELLER REINHOLD ,  DIGIAMMARINO ENRICO L ,  EBERT ULRICH ,  NIMMRICH VOLKER

IPC: C07K16/18 ,  C07K16/28 ,  C12N15/13 ,  C12N15/63 ,  C12N1/14 ,  C12P21/02 ,  A61K39/395 ,  A61P25/28

Abstract: Prote¡nas aisladas, en particular anticuerpos monoclonales, en particular anticuerpos humanizados, con injertos de CDR, que se unen a una prote¡na RAGE. Espec¡ficamente, estos anticuerpos tienen la capacidad de inhibir la union de RAGE a sus diversos ligandos. Los anticuerpos, o porciones de los mismos, que se describen en la presente solicitud son de utilidad para el tratamiento de una enfermedad o trastorno caracterizado por, o inducido por, ligandos fisiopatologicos de RAGE, por ejemplo prote¡nas mal plegadas como el beta amiloide y productos finales de glicosilacion avanzada.

公开(公告)号：MX2008006957A

公开(公告)日：2008-10-20

申请号：MX2008006957

申请日：2006-11-30

Applicant: ABBOTT LAB

Inventor： HOLZMAN THOMAS F ,  HARLAN JOHN E ,  EDALJI ROHINTON P ,  OLEJNICZAK EDWARD T ,  PERADA-LOPEZ ANA ,  LABKVOSKY BORIS ,  YU LIPING

IPC: C07K14/47 ,  A61P25/00 ,  C07K16/18 ,  G01N33/53

Abstract: La presente invención se refiere a la clonación, expresión y aislamiento de formas recombinantes de proteína beta-amiloide conteniendo una metionina N-terminal (o uno o más aminoácidos) así como a métodos para utilizar esta proteína recombinante en la producción de anticuerpos terapéuticos, en la identificación de moléculas pequeñas terapéuticas, y en la realización de ensayos de diagnóstico.